CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - CareDx reported revenue of $100.06 million for the quarter ended September 2025, reflecting a year-over-year increase of 20.7% [1] - The earnings per share (EPS) for the quarter was $0.28, up from $0.14 in the same quarter last year, indicating a significant improvement [1] - The revenue exceeded the Zacks Consensus Estimate of $95.23 million by 5.07%, while the EPS surpassed the consensus estimate of $0.13 by 115.38% [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $15.41 million, exceeding the three-analyst average estimate of $13.63 million, with a year-over-year change of 29.9% [4] - Revenue from Testing Services reached $72.17 million, surpassing the three-analyst average estimate of $69.48 million, representing an 18.7% increase year over year [4] - Revenue from Products was $12.48 million, slightly above the average estimate of $12.13 million from three analysts, showing a year-over-year change of 22.2% [4] Stock Performance - CareDx shares have returned -1.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]